Adenomatous Polyposis Coli
📧 Sign up to get email alerts when something new happens for Adenomatous Polyposis Coli.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2021-12-07EMA Application withdrawn: Flynpovi (eflornithine hydrochloride;sulindac) — Cancer Prevention Pharma (Ireland) Limited
EMA withdrew the application for Flynpovi (eflornithine hydrochloride; sulindac) for Adenomatous Polyposis Coli.
-
CLINICAL_TRIALS trial_result · 2019-09-20Clinical Trial Update: A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED) [Phase 4]
A Phase 4 trial of rofecoxib in familial adenomatous polyposis (Adenomatous Polyposis Coli) was terminated.
-
CLINICAL_TRIALS trial_result · 2014-11-03Clinical Trial Update: Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP) [Phase 3]
Phase 3 pediatric trial in familial adenomatous polyposis (Adenomatous Polyposis Coli) was terminated; results posted in 2014.
-
EMA withdrawal · 2011-04-06EMA Withdrawn: Onsenal (celecoxib) — Pfizer Limited
The EMA has withdrawn Onsenal (celecoxib) from consideration/market in 2011 under Pfizer Limited.